Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Kristen Detweiler-Short"'
Autor:
Dominik Dytfeld, Jagoda Jasielec, Kent A. Griffith, Daniel Lebovic, David H. Vesole, Sundar Jagannath, Ammar Al-Zoubi, Tara Anderson, Kristen Detweiler-Short, Keith Stockerl-Goldstein, Asra Ahmed, Terri Jobkar, Diane E. Durecki, Kathryn McDonnell, Melissa Mietzel, Daniel Couriel, Mark Kaminski, Ravi Vij, Andrzej J. Jakubowiak
Publikováno v:
Haematologica, Vol 99, Iss 9 (2014)
Externí odkaz:
https://doaj.org/article/cf62ec29a3d7487d9a6e4c425a2af9ae
Autor:
S. Vincent Rajkumar, Angela Dispenzieri, Vivek Roy, Joseph R. Mikhael, Philip R. Greipp, P. Leif Bergsagel, Rafael Fonseca, Robert A. Kyle, David Dingli, Craig B. Reeder, Steven R. Zeldenrust, Suzanne R. Hayman, A. Keith Stewart, Francis K. Buadi, Morie A. Gertz, John A. Lust, Shaji Kumar, Martha Q. Lacy, Stephen J. Russell, Thomas E. Witzig, Kristen Detweiler Short, Robert J. Dalton
Publikováno v:
Mayo Clinic Proceedings. 84:1095-1110
Multiple myeloma is a malignant plasma cell neoplasm that affects more than 20,000 people each year and is the second most common hematologic malignancy. It is part of a spectrum of monoclonal plasma cell disorders, many of which do not require activ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49846c77ef361062ce86a2c23b167792
https://doi.org/10.4065/mcp.2009.0603
https://doi.org/10.4065/mcp.2009.0603
Autor:
Kristen Detweiler-Short, Melissa A. Mietzel, Asra Ahmed, Daniel Lebovic, David H. Vesole, Ravi Vij, Dominik Dytfeld, Terri L. Jobkar, Keith Stockerl-Goldstein, Sundar Jagannath, Kathryn McDonnell, Andrzej Jakubowiak, Mark S. Kaminski, Ammar Al-Zoubi, Daniel R. Couriel, Tara B. Anderson, Jagoda Jasielec, Diane E. Durecki, Kent A. Griffith
Publikováno v:
Haematologica. 99(9)
A number of combination regimens with immunomodulatory agents or proteasome inhibitors have been developed for use in elderly patients with newly diagnosed multiple myeloma (NDMM). Regimens including bortezomib, melphalan, and prednisone (VMP), and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::996f7a43042f9f0b2f42e73598f28f9a
https://pubmed.ncbi.nlm.nih.gov/24972772
https://pubmed.ncbi.nlm.nih.gov/24972772
Autor:
Frances Buadi, Stephen R. Zeldenrust, Morie A. Gertz, Martha Q. Lacy, Kristen Detweiler-Short, Nelson Leung, John A. Lust, Robert A. Kyle, Stephen J. Russell, Shaji Kumar, S. Vincent Rajkumar, Suzanne R. Hayman, Angela Dispenzieri, David Dingli
Publikováno v:
American Journal of Hematology. 85:757-759
We evaluated the capability of soluble cardiac biomarkers to predict tolerability and outcomes of IMiD-containing treatments among 106 patients treated on clinical trials. Baseline elevations in troponin T (TnT) and N-terminal brain naturietic protei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b328f1fbaf8b1f72d56515db87856b50
https://doi.org/10.1002/ajh.21822
https://doi.org/10.1002/ajh.21822
Autor:
Ravi Vij, Tara B. Anderson, Brian K. Nordgren, Daniel R. Couriel, Kristen Detweiler-Short, Melissa A. Mietzel, Keith Stockerl-Goldstein, Terri L. Jobkar, Andrzej Jakubowiak, Sundar Jagannath, Diane E. Durecki, Mark S. Kaminski, Ammar Al-Zoubi, Daniel Lebovic, Kathryn McDonnell, Kent A. Griffith, Dominik Dytfeld, Asra Ahmed, David H. Vesole
This phase 1/2 study in patients with newly diagnosed multiple myeloma (N = 53) assessed CRd—carfilzomib (20, 27, or 36 mg/m2, days 1, 2, 8, 9, 15, 16 and 1, 2, 15, 16 after cycle 8), lenalidomide (25 mg/d, days 1-21), and weekly dexamethasone (40/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3495fce8557d4e273bfabc7796acffa3
https://europepmc.org/articles/PMC5162553/
https://europepmc.org/articles/PMC5162553/
Autor:
Joseph R. Mikhael, Kristen Detweiler-Short, Francis K. Buadi, Sutapa Sinha, Morie A. Gertz, Angela Dispenzieri, Martha Q. Lacy, S V Rajkumar, Shaji Kumar, S.R. Hayman, D. Dingli
Publikováno v:
Leukemia. 26(4)
Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::896fbe1ef68905d37552b277e4be0c51
https://pubmed.ncbi.nlm.nih.gov/21986842
https://pubmed.ncbi.nlm.nih.gov/21986842
Autor:
David Dingli, Shaji Kumar, Martha Q. Lacy, Philip R. Greipp, Sumit Madan, Morie A. Gertz, Francis K. Buadi, S. Vincent Rajkumar, Kristen Detweiler-Short, Angela Dispenzieri, John A. Lust, Steven R. Zeldenrust, Suzanne R. Hayman
The efficacy of retreatment with immunomodulatory drugs (IMiDs) among patients with multiple myeloma who received this class of drugs for initial therapy is unknown. We studied 140 patients who received either thalidomide-dexamethasone (81; 58%) or l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4f4351beeadc3e42a20365415475fa7
https://europepmc.org/articles/PMC3158710/
https://europepmc.org/articles/PMC3158710/
Autor:
Kristen Detweiler-Short, Angela Dispenzieri, Morie A. Gertz, Martha Q. Lacy, Steven R. Zeldenrust, Thomas E. Witzig, John A. Lust, Shaji Kumar, S. Vincent Rajkumar, Stephen J. Russell, Suzanne R. Hayman, Philip R. Greipp, Robert A. Kyle
We report the long-term follow-up results of a phase II trial of thalidomide for early-stage multiple myeloma (MM). Patients were eligible if they had smoldering multiple myeloma (SMM) or indolent MM without the need for immediate therapy. Thalidomid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::364c96645f46b1270c50d967cce2ed75
https://europepmc.org/articles/PMC3022372/
https://europepmc.org/articles/PMC3022372/
Autor:
Shaji Kumar, Morie A. Gertz, P L Bergsagel, Sumithra J. Mandrekar, Steven R. Zeldenrust, P R Greipp, Joseph R. Mikhael, R Fonseca, Stephen J. Russell, Martha Q. Lacy, Suzanne R. Hayman, Vivek Roy, Alexander Keith Stewart, Angela Dispenzieri, John A. Lust, S V Rajkumar, Kristen Detweiler Short, Francis K. Buadi, David Dingli, K M Laumann, Jake Allred
Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has significant activity in relapsed myeloma and previous studies suggest activity in lenalidomide refrac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ed48caffb20605a9df16fd0248979b7
https://europepmc.org/articles/PMC2978257/
https://europepmc.org/articles/PMC2978257/
Autor:
David J. Inwards, Svetomir N. Markovic, Morie A. Gertz, Steven R. Zeldenrust, Thomas M. Habermann, Craig B. Reeder, David Dingli, Robert J. Dalton, William G. Morice, Carrie A. Thompson, Stephen M. Ansell, Philip R. Greipp, Angela Dispenzieri, Martha Q. Lacy, Ivana N. Micallef, Shaji Kumar, Thomas E. Witzig, P. Leif Bergsagel, Joseph P. Colgan, John A. Lust, Robert A. Kyle, Rafael Fonseca, Patrick B. Johnston, Grzegorz S. Nowakowski, Suzanne R. Hayman, Stephen J. Russell, S. Vincent Rajkumar, Vivek Roy, Francis K. Buadi, Joseph R. Mikhael, A. Keith Stewart, Kristen Detweiler Short, Luis F. Porrata
Publikováno v:
Mayo Clinic proceedings. 85(9)
Waldenstrom macroglobulinemia is a B-cell malignancy with lymphoplasmacytic infiltration in the bone marrow or lymphatic tissue and a monoclonal immunoglobulin M protein (IgM) in the serum. It is incurable with current therapy, and the decision to tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::808d52a8ad7b42419d3ec8808430371a
https://pubmed.ncbi.nlm.nih.gov/20702770
https://pubmed.ncbi.nlm.nih.gov/20702770